Therapicon Srl
Main menu:
Modified recombinant human lysozyme
This invention relates to the modification of recombinant human lysozyme (rHLys) by reacting with activated polyethylene glycols (PEGs), which are partially binding or saturating the free amino groups of rHLys chain. The resulting conjugate compounds of the invention (PEG-rHLys) and their addition salts, inhibit through an unknown mechanism the abnormal cell proliferation and exhibit remarkably both antiproliferative and antimetastatic effects.
The invention relates also to the use of the new compounds in the preparation of pharmaceutical compositions for treating a disease associated with abnormal cell proliferation, including cancer, by administering therapeutically effective doses of said conjugates. The product, as immunological modifier, can be conveniently associated as adjuvant to the conventional anticancer protocols, in view of its negligible toxicity profile.
Therapicon® is a registered trade-mark in Italy and at OMPI (WIPO)-Geneva